CA2661012C - Method of treating stroke with thrombolytic agent - Google Patents

Method of treating stroke with thrombolytic agent Download PDF

Info

Publication number
CA2661012C
CA2661012C CA2661012A CA2661012A CA2661012C CA 2661012 C CA2661012 C CA 2661012C CA 2661012 A CA2661012 A CA 2661012A CA 2661012 A CA2661012 A CA 2661012A CA 2661012 C CA2661012 C CA 2661012C
Authority
CA
Canada
Prior art keywords
tenecteplase
dose
infusion
ischemic stroke
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2661012A
Other languages
English (en)
French (fr)
Other versions
CA2661012A1 (en
Inventor
Peter Kuebler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2661012(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CA2661012A1 publication Critical patent/CA2661012A1/en
Application granted granted Critical
Publication of CA2661012C publication Critical patent/CA2661012C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2661012A 2006-08-29 2007-08-01 Method of treating stroke with thrombolytic agent Expired - Fee Related CA2661012C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82386806P 2006-08-29 2006-08-29
US60/823,868 2006-08-29
PCT/US2007/074997 WO2008027687A2 (en) 2006-08-29 2007-08-01 Use of tenecteplase for treating acute ischemic stroke

Publications (2)

Publication Number Publication Date
CA2661012A1 CA2661012A1 (en) 2008-03-06
CA2661012C true CA2661012C (en) 2019-03-19

Family

ID=38835003

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2661012A Expired - Fee Related CA2661012C (en) 2006-08-29 2007-08-01 Method of treating stroke with thrombolytic agent

Country Status (21)

Country Link
US (2) US20080107641A1 (https=)
EP (1) EP2056856B1 (https=)
JP (1) JP5785687B2 (https=)
KR (1) KR20090045405A (https=)
CN (1) CN101505785A (https=)
AU (1) AU2007290277B2 (https=)
BR (1) BRPI0716143A2 (https=)
CA (1) CA2661012C (https=)
CO (1) CO6150188A2 (https=)
EA (1) EA015573B1 (https=)
EC (1) ECSP099178A (https=)
IL (2) IL196987A (https=)
MX (1) MX2009001918A (https=)
MY (1) MY163119A (https=)
NO (1) NO342302B1 (https=)
NZ (1) NZ574767A (https=)
SG (3) SG10201804944XA (https=)
TW (1) TWI439282B (https=)
UA (1) UA97486C2 (https=)
WO (1) WO2008027687A2 (https=)
ZA (1) ZA200900957B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EP2540696B1 (en) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans carotenoids, formulation and uses
BRPI0716143A2 (pt) 2006-08-29 2013-11-26 Genentech Inc Uso de tenecteplase para tratar derrame isquêmico agudo
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
US9034007B2 (en) 2007-09-21 2015-05-19 Insera Therapeutics, Inc. Distal embolic protection devices with a variable thickness microguidewire and methods for their use
US20110257510A1 (en) * 2008-12-24 2011-10-20 Koninklijke Philips Electronics N.V. System, method and apparatus for cardiac intervention with mr stroke detection and treatment
EP2445339B1 (en) * 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
EP2470015B1 (en) * 2009-08-24 2016-01-13 Hough Ear Institute Nitrone compounds for treating sensorineural hearing loss
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
JP6375112B2 (ja) * 2010-12-23 2018-08-15 ジェノヴァ バイオファーマシューティカルズ リミテッド テネクテプラーゼの医薬組成物
WO2014062888A1 (en) * 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
US8690907B1 (en) 2013-03-15 2014-04-08 Insera Therapeutics, Inc. Vascular treatment methods
US8679150B1 (en) 2013-03-15 2014-03-25 Insera Therapeutics, Inc. Shape-set textile structure based mechanical thrombectomy methods
CA2901443A1 (en) 2013-03-15 2014-09-25 Insera Therapeutics, Inc. Vascular treatment devices and methods
US8715314B1 (en) 2013-03-15 2014-05-06 Insera Therapeutics, Inc. Vascular treatment measurement methods
WO2015023830A1 (en) 2013-08-14 2015-02-19 Stc.Unm Treatment and prevention of stroke and other neurological disorders
PL3209767T3 (pl) * 2014-10-21 2021-01-11 Gennova Biopharmaceuticals Ltd. Nowy sposób oczyszczania do izolacji i komercyjnej produkcji zrekombinowanego tnk-tpa (tenekteplazy)
EP3416568A4 (en) 2016-02-16 2019-10-16 Insera Therapeutics, Inc. SUCTION DEVICES AND ANCHORED FLOW REVERSING DEVICES
CA3018550A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
EP3936140B1 (en) * 2017-01-24 2023-08-30 Boston Scientific Scimed, Inc. Thrombolytic agent for the treatment of thromboembolism
EP3624832B1 (en) * 2017-05-16 2025-08-20 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of acute ischemic stroke
US10426424B2 (en) 2017-11-21 2019-10-01 General Electric Company System and method for generating and performing imaging protocol simulations
US20230068460A1 (en) * 2020-02-04 2023-03-02 The Regents Of The University Of Colorado, A Body Corporate Prophylactic uses of annexin a2
IL295727A (en) * 2020-02-19 2022-10-01 Nono Inc Combined treatment of stroke with a plasmin-degradable and reperfusion psd-95 inhibitor
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用
CN115487294A (zh) * 2022-07-12 2022-12-20 上海丰华天力通生物医药有限公司 替奈普酶在制备用于治疗轻型缺血性卒中的药物组合物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE155816T1 (de) 1992-06-03 1997-08-15 Genentech Inc Varianten des gewebeplasminogenaktivators mit verbesserter therapeutischer wirkung
JP2002173447A (ja) * 2000-09-29 2002-06-21 Yamanouchi Pharmaceut Co Ltd 脳塞栓症治療用医薬組成物
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20030180282A1 (en) * 2002-03-25 2003-09-25 Victor Serebruany Method of treatment of thrombotic events
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
BRPI0716143A2 (pt) 2006-08-29 2013-11-26 Genentech Inc Uso de tenecteplase para tratar derrame isquêmico agudo

Also Published As

Publication number Publication date
AU2007290277B2 (en) 2013-04-11
CO6150188A2 (es) 2010-04-20
EP2056856A2 (en) 2009-05-13
ECSP099178A (es) 2009-06-30
IL196987A (en) 2016-10-31
BRPI0716143A2 (pt) 2013-11-26
SG10201501498VA (en) 2015-04-29
NZ574767A (en) 2012-02-24
ZA200900957B (en) 2010-05-26
US20080107641A1 (en) 2008-05-08
HK1131054A1 (en) 2010-01-15
NO20091296L (no) 2009-05-28
JP2010502629A (ja) 2010-01-28
CN101505785A (zh) 2009-08-12
TW200817033A (en) 2008-04-16
KR20090045405A (ko) 2009-05-07
MY163119A (en) 2017-08-15
CA2661012A1 (en) 2008-03-06
WO2008027687A3 (en) 2008-05-22
US20120164157A1 (en) 2012-06-28
US9023346B2 (en) 2015-05-05
UA97486C2 (ru) 2012-02-27
AU2007290277A1 (en) 2008-03-06
IL248176A0 (en) 2016-11-30
NO342302B1 (no) 2018-04-30
IL196987A0 (en) 2011-08-01
EA200970237A1 (ru) 2009-08-28
JP5785687B2 (ja) 2015-09-30
TWI439282B (zh) 2014-06-01
SG174753A1 (en) 2011-10-28
EP2056856B1 (en) 2015-01-14
EA015573B1 (ru) 2011-10-31
SG10201804944XA (en) 2018-07-30
WO2008027687A2 (en) 2008-03-06
MX2009001918A (es) 2009-03-06

Similar Documents

Publication Publication Date Title
CA2661012C (en) Method of treating stroke with thrombolytic agent
RU2166326C2 (ru) Комбинация тромболитически активных белков и антикоагулянтов
EP3395359A1 (en) Method for preventing or treating acute thrombosis and chronic thrombosis
Furlan et al. Thrombolytic therapy in acute ischemic stroke
US20200255530A1 (en) Compositions and methods for treatment of stroke and other cns disorders
Xu et al. Specific inhibition on PAI-1 reduces the dose of Alteplase for ischemic stroke treatment
EP2845601A1 (en) Composition for dissolving thrombi, and a pharmaceutical composition for treating stenotic or occlusive vascular diseases which comprises the same
Broderick Recanalization therapies for acute ischemic stroke
HK1131054B (en) Use of tenecteplase for treating acute ischemic stroke
KR20230048514A (ko) 뇌졸중 환자에서 사망의 위험을 감소시키기 위한 페를레칸 및 이의 단편의 용도
Brott Reopening occluded cerebral arteries
Clark et al. Medical treatment strategies: intravenous thrombolysis, neuronal protection, and anti-reperfusion injury agents
Spinler et al. Update on strategies to improve thrombolysis for acute myocardial infarction
HK40105798A (zh) 用於治疗脑梗塞的药物组合物
HK40119109A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
JP2022551373A (ja) 三環式誘導体を用いた脳卒中の治療方法
HK40099476A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
Weiner Thrombolytic agents in critical care
Diaz-Ricart Desmoteplase
WO2007134813A2 (en) Use of desmodus salivary plasminogen activator (dspa) for treating venous thromboembolism
WO2009046742A1 (en) Staphylokinase variant
KR20210014024A (ko) 트리사이클릭 유도체를 이용한 뇌졸중의 치료 방법
JP2008507561A (ja) 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
EP2289541A1 (en) Treatment of neurological or neurodegenerative disorders
Walsh Tissue Plasminogen Activator-Based Thrombolytic Agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210803